Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP

Pathology and Oncology Research

Volumn 17, Issue 2, 2011, Pages 243-247

  Mitrović, Zdravko ^a,b   Ilić, Ivana ^a   Aurer, Igor ^a,b   Kinda, Sandra Bašić ^a   Radman, Ivo ^a   Dotlić, Snježana ^a   Ajduković, Radmila ^c   Labar, Boris ^a  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c University of Zagreb School of Medicine   (Croatia)

Author keywords

Caspase 3; Diffuse large B cell lymphoma; Immunohistochemistry; Non Hodgkin's lymphoma; Prognostic factors; Rituximab; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; SURVIVIN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASPASE 3; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 80051669358     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-010-9304-4     Document Type: Article

References (22)

1. Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126 (Pubitemid 46211317)
2. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
3. Cvetkovic RS, Perry CM (2006) Rituximab-a review of its use in Non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 66:791-820 (Pubitemid 43778729)
4. Guha M, Altieri DC (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8:2708-2710
5. Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509-512 (Pubitemid 40349608)
6. Watanuki-Miyauchi R, Kojima Y, Tsurumi H et al (2005) Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 55:324-330 (Pubitemid 40910665)
7. Karabatsou K, Pal P, Dodd S et al (2006) Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor alpha in primary central nervous system lymphoma. J Neurooncol 79:171-179 (Pubitemid 44349946)
8. Lin L, Min Z, Ping Z (2007) Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 48:2179-2183
9. Mainou-Fowler T, Overman LM, Dignum H et al (2008) A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32:59-68 (Pubitemid 351176062)
10. Adida C, Haioun C, Gaulard P et al (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921-1925 (Pubitemid 30661078)
11. Aktas S, Kargi A, Olgun N et al (2009) Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr Virus positive and negative pediatric non-Hodgkin's lymphoma. Pathol Oncol Res 15:345-350
12. Paydas S, Seydaoglu G, Ergin M et al (2009) Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 33:1627-1635
13. Hans CP, Weisenburger DD, Greiner TC et al (2005) Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 18:1377-1384 (Pubitemid 41348658)
14. Krajewski S, Gascoyne RD, Zapeta JM et al (1997) Immunolocalisation of the ICE/Ced 3-family protease, CPP32 (Caspase-3) in non-Hodgkin lymphomas, Chronic lymphocytic leukemias and reactive lymph nodes. Blood 89:3817-3825
15. Donoghue S, Baden SH, Lauder I et al (1999) Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large cell lymphoma. Cancer Res 59:5386-5391 (Pubitemid 29504009)
16. Ten Berge RL, Meijer CJ, Dukers DF et al (2002) Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99:4540-4546 (Pubitemid 34627225)
17. Muris JJ, Cillessen SA, Vos W et al (2005) Immunohistochemical profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 105:2916-2923 (Pubitemid 40446286)
18. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working group. J Clin Oncol 17:1244-1253 (Pubitemid 29162950)
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-hodgkin's lymphoma. N Engl J Med 329:987-994
20. Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284 (Pubitemid 36857789)
21. Ansell SM, Arendt BK, Grote DM et al (2004) Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 18:616-623 (Pubitemid 38425878)
22. Tolcher AW, Mita A, Lewis LD et al (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198-5203